A Single and Multiple Ascending Dose Study of COR588
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Cortexyme Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT04920903
- Locations
- ๐ฆ๐บ
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease
Phase 2
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Drug: COR388 capsuleDrug: Placebo capsule
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Cortexyme Inc.
- Target Recruit Count
- 643
- Registration Number
- NCT03823404
- Locations
- ๐บ๐ธ
ATP Clinical Research, Inc., Costa Mesa, California, United States
๐บ๐ธPrinceton Medical Institute, Princeton, New Jersey, United States
๐บ๐ธRecognition Health, Fairfax, Virginia, United States
A Multiple Ascending Dose Study of COR388
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Cortexyme Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03418688
- Locations
- ๐บ๐ธ
Bioclinica Research, Orlando, Florida, United States
๐บ๐ธPacific Research Network, San Diego, California, United States
๐บ๐ธMedpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
Study of COR388 HCl in Healthy Subjects
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Cortexyme Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03331900
- Locations
- ๐บ๐ธ
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath